Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Felzartamab in Kidney Transplant Recipients With Late Antibody-Mediated Rejection (AMR)
NCT06685757Phase 3Active, not recruiting
- Sponsor
- Biogen
- Start
- Dec 2024
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
A Phase 3 trial of felzartamab in antibody mediated rejection (AMR), sponsored by Biogen. Started Dec 2024; status: active, not recruiting.
02
Drugs
felzartamab
03
Conditions
antibody mediated rejection (AMR)
Beyond the preview
Go deeper on NCT06685757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06685757.